

Prospective Study of Changes in the Metabolomic Profiles of Men during Their First Three Months of Androgen Deprivation Therapy for Prostate Cancer

Philip J. Saylor¹, Edward D. Karoly², and Matthew R. Smith¹

Abstract

Purpose: Androgen deprivation therapy (ADT) for prostate cancer causes an increase in fasting insulin and adverse changes in body composition and serum lipid profile. It is unknown what other metabolic alterations are caused by ADT. To better characterize the metabolic effects of ADT, we measured changes in plasma metabolomic profile at baseline and after the first 3 months of therapy.

Experimental Design: Fasting plasma samples were drawn from 36 subjects at baseline and after 3 months of gonadotropin releasing hormone (GnRH) agonist therapy. Extracted samples were split into equal parts for analysis on the gas chromatography-mass spectrometry and liquid chromatography/tandem mass spectrometry platforms.

Results: Of the 292 identified metabolites, 56 changed significantly ($P < 0.05$) from baseline to 3 months. Notable changes were grouped as follows: (i) Multiple steroids were lower at 3 months, consistent with the effect of therapy on gonadal androgen synthesis. (ii) Most bile acids and their metabolites were higher during treatment. Cholesterol levels changed very little. (iii) Markers of lipid beta-oxidation (acetyl-carnitines and ketone bodies) and omega-oxidation were lower at 3 months. (iv) Two previously identified biomarkers of insulin resistance (2-hydroxybutyrate and branch chain keto-acid dehydrogenase complex products) were stable to lower at 3 months.

Conclusions: Unbiased metabolomic analyses revealed expected, novel, and unexpected results. Steroid levels fell, consistent with the effects of ADT. Most bile acids and their metabolites increased during ADT, a novel finding. Biomarkers of lipid metabolism and insulin resistance fell, unexpected given that ADT has been shown to increase fasting insulin. *Clin Cancer Res*; 18(13); 3677–85. ©2012 AACR.

Introduction

Androgen deprivation therapy (ADT) is the foundational systemic therapy for men with prostate cancer. It can be accomplished with a gonadotropin releasing hormone (GnRH) agonist, a GnRH antagonist, or bilateral orchiectomy. ADT is associated with improved survival in combination with external beam radiation for intermediate or high-risk localized prostate cancer (1–7) and as monotherapy for metastatic disease (8, 9). Despite these benefits, ADT has been reproducibly shown to cause a number of adverse metabolic effects and may negatively impact the overall health of prostate cancer survivors.

GnRH agonist therapy most prominently causes adverse effects on body composition, serum lipid profile, and

insulin. Prospective studies have shown that ADT causes men to gain fat mass and lose lean muscle mass (10–13). ADT has also been shown to result in metabolic changes typical of obesity including increased serum cholesterol and triglycerides and increased fasting insulin (10, 14–16). Furthermore, population-based analyses have shown that GnRH agonist use is associated with higher incidence of diabetes and of coronary artery disease (17–23). These hypothesis-driven prior studies have focused on metabolic outcomes associated with obesity [e.g., hyperlipidemia and insulin resistance (IR)]. As a result of this limited scope, it is unknown what broader alterations are induced by ADT.

Metabolomics is a technique that allows for the unbiased study of small-molecule metabolites present in fluids or tissues. Current metabolomic methods can be used to screen broadly for changes in plasma hormones and metabolites of potential biologic significance in a variety of clinical settings. For example, this technique has previously been used to identify biomarkers of IR (24, 25) as well as a potential biomarker of prostate cancer progression (26). The metabolomic platform used in these studies incorporates mass spectrometry (MS) coupled with liquid (LC) and/or gas chromatography (GC) and bioinformatics software for compound identification (27).

Authors' Affiliations: ¹Division of Hematology-Oncology, Massachusetts General Hospital (MGH) Cancer Center, Boston, Massachusetts; and ²Metabolon, Inc., Morrisville, North Carolina

Corresponding Author: Philip J. Saylor, Massachusetts General Hospital, Yawkey 7E, 55 Fruit Street, Boston, MA 02114. Phone: 617-724-4000; Fax: 617-726-8685; E-mail: psaylor@partners.org

doi: 10.1158/1078-0432.CCR-11-3209

©2012 American Association for Cancer Research.

Translational Relevance

In this study, we present the results of metabolomic analyses that were used to broadly screen for changes in metabolically relevant biochemicals during the first 3 months of androgen deprivation therapy (ADT) for prostate cancer. We found that ADT was associated with increased levels of a number of bile acids and decreased levels of previously identified markers of insulin resistance (IR) and lipid beta-oxidation. The translational significance of these findings can be expressed in two primary ways. First, changes in bile acid levels may be among the important metabolic effects of ADT and may, with further study, become a target for therapeutic intervention. Second, unexpected changes in biomarkers of lipid oxidation and IR reveal that therapeutic induction of severe hypogonadism, using a GnRH agonist, causes patterns of disordered metabolism that are distinct from those produced by chronic onset IR in the general population.

We hypothesized that metabolomic analyses following initiation of a GnRH agonist would reveal treatment-induced perturbations in biochemical pathways that had not previously been associated with ADT. To more broadly characterize the metabolic effects of ADT, we measured fasting plasma metabolomic profiles at baseline and after the first 3 months of ADT in men with prostate cancer. This time frame was chosen because body composition (28), lipid profile (16), and fasting insulin (14) all change within months of ADT initiation. Changes in relative risks for diabetes and coronary artery disease with just 3 months of ADT cannot be assessed with currently available data. Characterization of the metabolomic signature of patients receiving ADT has the potential to generate new insights that would not be possible within more narrowly focused testing. It may facilitate discovery of biomarkers of host metabolic changes. Furthermore, identification of such biomarkers has the potential to produce clinically relevant mechanistic insights.

Materials and Methods

Study participants were recruited and gave written informed consent at Massachusetts General Hospital (MGH; Boston, MA) with Institutional Review Board approval. All subjects had locally advanced or recurrent adenocarcinoma of the prostate and were planned for 3 or more months of ADT with a GnRH agonist. Exclusion criteria included scan-detectable bone metastases, Karnofsky performance status less than 90, history of diabetes or glucose intolerance, treatment with medications known to alter glucose or insulin levels, and history of prior hormonal therapy for prostate cancer within the past year.

A total of 36 subjects met the eligibility criteria and took part in the study. Subjects were evaluated at the MGH

Clinical Research Center at baseline and after 3 months of ADT (range, 71–112 days). All participants were receiving ongoing ADT with a GnRH agonist at the time of repeat testing. Fasting blood samples were collected on the morning of each visit and were stored at -70°C for subsequent batch measurements. After the baseline visit, subjects received leuprolide 3-month depot (Lupron Depot; TAP Pharmaceuticals Inc.; 22.5 mg intramuscularly). Subjects also received bicalutamide (Casodex; AstraZeneca PLC; 50 mg *per os* daily) for 4 weeks to prevent effects of androgen flare associated with initiation of a GnRH agonist.

Metabolomic analyses were conducted by Metabolon, Inc. as reported previously (29).

Sample preparation

Each sample is accessioned into a Laboratory Information Management System (LIMS) system, assigned a unique identifier, and stored at -70°C . To remove protein, dissociate small molecules bound to protein or trapped in the precipitated protein matrix, and to recover chemically diverse metabolites, proteins are precipitated with methanol with vigorous shaking for 2 minutes (Glen Mills Genogrinder 2000). The sample is then centrifuged, supernatant removed (MICROLAB STAR robotics), and split into 4 equal volumes. All biologic samples were then randomized across a 2-day run and analyzed in this order across each of the LC+, LC-, and GC platforms. One aliquot is retained for backup analysis, if needed.

Liquid chromatography/tandem mass spectrometry LC/MS-MS and GC/MS

The LC/MS portion of the platform incorporates a Waters ACQUITY UPLC System and a Thermo Finnigan LTQ Mass Spectrometer, including an electrospray ionization source and linear ion-trap mass analyzer. Aliquots of the vacuum-dried sample are reconstituted, one each in acidic or basic LC-compatible solvents containing 8 or more injection standards at fixed concentrations (to both ensure injection and chromatographic consistency). The acidic extracts were monitored for positive ions (LC+) and basic extracts were monitored for negative ions (LC-). Extracts are loaded onto columns (Waters UPLC BEH C18–2.1 \times 100 mm, 1.7 μm) and gradient-eluted with water and 95% methanol containing 0.1% formic acid (acidic extracts) or 6.5 mmol/L ammonium bicarbonate (basic extracts). Samples for GC/MS analysis are dried under vacuum desiccation for a minimum of 18 hours before being derivatized under nitrogen using bistrimethyl-silyl-trifluoroacetamide. Injection standards at fixed concentrations to monitor the injection and chromatographic consistency were also included. The GC column is 5% phenyl dimethyl silicone and the temperature ramp is from 60°C to 340°C in a 17-minute period. All samples are then analyzed on a Thermo Finnigan Trace DSQ Fast-Scanning Single-Quadrupole Mass Spectrometer using electron impact ionization. The instrument is tuned and calibrated for mass resolution and mass accuracy daily.

Quality control

All columns and reagents are purchased in bulk from a single lot to complete all related experiments. Instrument variability was determined by calculating the median relative standard deviation (RSD) for the internal standards that were added to each sample before injection into the mass spectrometers. Also included were several technical replicate samples created from a homogeneous pool containing a small amount of all study samples ("Client Matrix"). Overall process variability was determined by calculating the median RSD for all endogenous metabolites (i.e., non-instrument standards) present in 100% of the Client Matrix samples, which are technical replicates of the pooled client samples. Values for instrument and process variability in association with these samples meet Metabolon's acceptance criteria. Specifically, instrument variability for the internal standards was found to have a median RSD of 7%. Total process variability for the endogenous biochemicals was found to have a median RSD of 18%.

Bioinformatics

The LIMS system encompasses sample accessioning, preparation, instrument analysis and reporting, and advanced data analysis. Additional informatics components include data extraction into a relational database and peak-identification software, proprietary data processing tools for quality control (QC) and compound identification, and a collection of interpretation and visualization tools for use by data analysts. The hardware and software systems are built on a web service platform using Microsoft's .NET technologies, which run on high-performance application servers and fiber-channel storage arrays in clusters, to provide active failover and load balancing.

Compound identification, quantification, and data curation

Biochemicals are identified by comparison to library entries of purified standards. At present, more than 2,400 commercially available purified standards are registered into LIMS for distribution to both the LC and GC platforms for determination of their analytic characteristics. Chromatographic properties and mass spectra allow matching to the specific compound or an isobaric entity using proprietary visualization and interpretation software. Additional recurring entities may be identified as needed via acquisition of a matching purified standard or by classical structural analysis. Peaks are quantified using area under the curve. Subsequent QC and curation processes are designed to ensure accurate, consistent identification, and to minimize system artifacts, misassignments, and background noise. Library matches for each compound are verified for each sample.

Statistical analysis

Missing values (if any) are assumed to be below the level of detection. However, biochemicals that were detected in all samples from one or more groups, but not in samples from other groups, were assumed to be near the lower limit of detection in the groups in which they were not detected.

In this case, the lowest detected level of these biochemicals was imputed for samples in which that biochemical was not detected. On the basis of this, please note that our method of imputation does generate fold-change values that may be conservative in nature.

Biochemicals were mapped to pathways on the basis of Kyoto Encyclopedia of Genes and Genomes (KEGG), given the multiple comparisons inherent in analysis of metabolites. Values for each compound were normalized by calculating the median of the values that were generated on each individual run day ("block normalization"). This normalization step was conducted to correct variation resulting from instrument inter-day tuning differences. Essentially, each compound was corrected in run-day blocks by registering the medians to equal one (1.00) and normalizing each data point proportionately. Missing values were assumed to be below the level of detection for that compound with the instrumentation used. Missing values were imputed with the observed minimum for that compound and added after block normalization. Biochemical fold differences were generated on the basis of group means after imputation with ratios greater than one representing fold increases, whereas ratios less than one show fold decreases. Matched pairs *t* tests were conducted to identify biochemicals that differed between baseline and after 3 months of ADT when comparing the metabolic profiles of participant plasma samples. *P* values <0.05 were considered statistically significant.

Results

A total of 504 metabolites were observed. Of these, 292 were identified as named metabolites within the Metabolon library. The remaining 212 metabolites were classified as unidentified, reflecting expected limitations of the platform's compound library. Plasma levels of 88 biochemicals changed significantly (14 rose and 74 fell; *P* < 0.05 for each) from baseline to 3 months. Of those 88 biochemicals, 56 were identified compounds (9 rose and 47 fell) and 32 were unidentified compounds (5 rose and 27 fell). Consistent changes in identified biochemicals were grouped thematically on the basis of investigator judgment into the following 4 categories:

- (i) **Steroid levels:** Levels of multiple steroids were significantly lower at 3 months compared with baseline (see Table 1). Cholesterol levels changed very little with treatment (1.06-fold change, *P* = 0.029). Significant decreases were observed for the following sulfated sterols: dehydroepiandrosterone sulfate (DHEAS), epiandrosterone sulfate, androsterone sulfate, cortisol, 4-androsten-3 β ,17 β -diol disulfates 1 & 2, 5 α -androstan-3 β ,17 β -diol disulfate, pregnen-diol disulfate, pregn-steroid monosulfate, and androsteroid monosulfates 1 & 2. Testosterone was not detected at either time point.
- (ii) **Bile acids and intermediates of bile acid metabolism increased:** Most bile acids and their metabolites that

Table 1. Changes in steroids from baseline to 3 months

Subpathway	Biochemical name	Fold of change, month 3 versus baseline	P value for paired t test, month 3 versus baseline	q value for paired t test, month 3 versus baseline
Sterol/Steroid	Cholesterol	1.06	0.029	0.120
	Dehydroisoandrosterone sulfate (DHEA-S)	0.87	<0.001	0.002
	Epiandrosterone sulfate	0.50	<0.001	<0.001
	Androsterone sulfate	0.50	<0.001	<0.001
	Cortisol	0.84	0.012	0.072
	Cortisone	0.89	0.369	0.370
	7-alpha-hydroxy-3-oxo-4-cholestenoate (7-Hoca)	1.01	0.653	0.478
	4-androsten-3beta,17beta-diol disulfate 1	0.87	<0.001	0.003
	4-androsten-3beta,17beta-diol disulfate 2	0.70	<0.001	<0.001
	5-alpha-androstan-3beta,17beta-diol disulfate	0.33	<0.001	<0.001
	Pregnen-diol disulfate	0.76	<0.001	<0.001
	Pregn-steroid monosulfate	0.76	<0.001	<0.001
	Andro-steroid monosulfate 1	0.88	0.029	0.120
	Andro-steroid monosulfate 2	0.93	0.321	0.356

NOTE: All values are normalized in terms of raw area counts. "Fold change month 3 versus baseline" denotes month 3 level divided by baseline level of each biochemical name (i.e., fold change of 0.76 denotes a 24% decrease). Biochemical fold differences were generated based on group means with ratios greater than one representing fold increases and ratios less than one representing fold decreases. Metabolites that exhibited statistically significant changes are bolded.

were identified by this analysis were higher during treatment (see Table 2), though most were not statistically significant. Increases were detected in cholate, glycocholate, taurocholate, chenodeoxycholate, taurochenodeoxycholate, ursodeoxycholate, hyodeoxycholate, deoxycholate, taurodeoxycholate glycodeoxycholate, glycochenodeoxycholate, 7-ketodeoxycholate, glycochenodeoxycholate, glycolithocholate sulfate, and tauroolithocholate 3-sulfate. The rise in cholate was statistically significant. Glycocholate sulfate and taurocholate sulfate each fell slightly.

(iii) *Markers of lipid oxidation:* Several indications of lipid metabolism were lower at 3 months compared with baseline (see Table 3):

- Carnitine metabolism: Acyl carnitines function as chaperones for fatty-acyl Co-A transport into the mitochondrion, where beta-oxidation takes place. Several acyl carnitines were significantly lower following ADT, including deoxycarnitine, acetylcarnitine, hexanoylcarnitine, octanoylcarnitine,

decanoylcarnitine, laurylcarnitine, palmitoylcarnitine, stearoylcarnitine, and oleoylcarnitine ($P < 0.05$ for each compound).

- Ketone bodies: beta-oxidation of fatty acids produces ketone bodies as byproducts. Ketone bodies 3-hydroxybutyrate (BHBA) and acetoacetate were significantly lower following ADT ($P < 0.05$ for each).
 - Dicarboxylic acids: omega-oxidation is a secondary pathway to fatty acid metabolism. omega-oxidation produces dicarboxylic acids (DCA) as byproducts. Two DCAs (dodecanedioate and octadecanedioate; $P < 0.05$ for each) were significantly lower following ADT.
- (iv) *Markers of IR:* Biomarkers of 2 key processes relevant to IR were lower or stable at 3 months than at baseline (see Table 4). 2-hydroxybutyrate (2-HB, or AHB; ref. 24) and branch chain keto-acid dehydrogenase (BCKDH) complex products (25) have previously been associated with IR. 2-HB is an organic acid and can be a byproduct of

Table 2. Changes in bile acids from baseline to 3 months

Subpathway	Biochemical name	Fold of change, month 3 versus baseline	P value for paired t test, month 3 versus baseline	q value for paired t test, month 3 versus baseline
Bile acid metabolism	Cholate	1.94	0.023	0.107
	Glycocholate	1.27	0.976	0.553
	Taurocholate	2.08	0.435	0.404
	Chenodeoxycholate	1.19	0.189	0.310
	Taurochenodeoxycholate	1.70	0.698	0.498
	Ursodeoxycholate	1.57	0.088	0.222
	Hyodeoxycholate	1.33	0.089	0.222
	Deoxycholate	1.36	0.398	0.382
	Taurodeoxycholate	1.21	0.311	0.356
	Glycodeoxycholate	1.19	0.660	0.481
	7-ketodeoxycholate	1.06	0.208	0.324
	Glycochenodeoxycholate	1.48	0.136	0.269
	Glycolithocholate sulfate	1.12	0.634	0.468
	Taurolithocholate 3-sulfate	1.16	0.982	0.554
	Glycochenolate sulfate	0.96	0.372	0.370
	Taurochenolate sulfate	0.85	0.128	0.266

NOTE: All values are normalized in terms of raw area counts. "Fold change month 3 versus baseline" denotes month 3 level divided by baseline level of each biochemical name (i.e., fold change of 0.76 denotes a 24% decrease). Biochemical fold differences were generated based on group means with ratios greater than one representing fold increases and ratios less than one representing fold decreases. Metabolites that exhibited statistically significant changes are bolded.

2-ketobutyrate (α -KB) production. α -KB itself can be produced by amino acid catabolism. 2-HB generally increases during states of disrupted metabolism (e.g., lactic acidosis and ketoacidosis) or in the presence of an elevated NADH/NAD⁺ ratio (30). Treatment levels of 2-HB were significantly lower than baseline levels (0.84-fold change, $P = 0.03$). BCKAs are a major component of skeletal muscle and tend to increase in plasma during fasting and/or protein catabolism (31). Many components of branched chain amino acid metabolism did not change significantly, whereas 2 were significantly lower on treatment than at baseline (α -hydroxyisovalerate, 2-methylbutyrylcarnitine; $P < 0.05$ for each).

Discussion

We carried out unbiased metabolomic analyses on fasting plasma samples from 36 men with prostate cancer at baseline and after 3 months of ADT. These analyses revealed expected, novel, and unexpected results. Steroid levels fell, consistent with the effects of ADT. We observed novel evidence of increased levels of bile acids and bile acid metabolites. Biomarkers of fatty acid oxidation and IR were stable to decreased, unexpected results given that ADT has previously been shown to increase fasting insulin. To the best of our knowledge, this is the first study to use meta-

bolomics to characterize the metabolic alterations with ADT.

We found that a number of steroids decreased during ADT. This finding reflects the intended effect of ADT. This expected observation within unbiased metabolomic analyses supports the experimental methodology.

We observed that numerous bile acids and their metabolites were higher during ADT for prostate cancer than at baseline. To our knowledge, this is a novel finding. There are a number of potential implications of the observed increase in bile acids.

Bile acids are well known for their role in solubilizing fats within the digestive tract. Primary bile acids are synthesized by the liver and secreted into the duodenum where they form micelles that aid in the digestion and absorption of dietary fats. Primary bile acids can be modified by intestinal flora to produce secondary and tertiary bile acids. All types are efficiently reabsorbed in the terminal ileum to continue within the enterohepatic circulation. Bile acids also function as hormones that are important in modulating a number of metabolic processes.

The concept of bile acids as regulatory hormones is relatively new. Among other receptors, they bind to both the nuclear farnesoid X receptor (FXR) and to a cell surface membrane G-protein-coupled receptor (TGR5) in a variety of target tissues. Bile acid signaling through these receptors seems to play important roles in regulating serum lipids, glycemic control, and energy homeostasis (32). ADT for

Table 3. Changes in markers of fatty acid oxidation from baseline to 3 months

Subpathway	Biochemical name	Fold of change, month 3 versus baseline	P value for paired t test, month 3 versus baseline	q value for paired t test, month 3 versus baseline
Carnitine metabolism	Deoxycarnitine	0.89	0.023	0.107
	Carnitine	1.01	0.799	0.512
	3-dehydrocarnitine	0.93	0.266	0.356
	Acetylcarnitine	0.80	<0.001	0.011
	Hexanoylcarnitine	0.80	0.002	0.026
	Octanoylcarnitine	0.72	<0.001	0.011
	Decanoylcarnitine	0.71	<0.001	0.003
	Laurylcarnitine	0.65	0.003	0.029
	Palmitoylcarnitine	0.82	0.041	0.144
	Stearoylcarnitine	0.77	0.004	0.035
Ketone bodies	3-hydroxybutyrate (BHBA)	0.36	0.009	0.063
	Acetoacetate	0.52	0.002	0.020
Fatty acid, dicarboxylate	2-hydroxyglutarate	0.96	0.728	0.508
	Sebacate (decanedioate)	0.85	0.360	0.366
	Dodecanedioate	0.80	0.016	0.092
	Tetradecanedioate	0.72	0.105	0.237
	Hexadecanedioate	0.67	0.053	0.168
	Octadecanedioate	0.73	<0.001	0.001
	3-carboxy-4-methyl-5-propyl-2-furanpropanoate	0.88	0.451	0.408

NOTE: All values are normalized in terms of raw area counts. "Fold change month 3 versus baseline" denotes month 3 level divided by baseline level of each biochemical name (i.e., fold change of 0.76 denotes a 24% decrease). Biochemical fold differences were generated based on group means with ratios greater than one representing fold increases and ratios less than one representing fold decreases. Metabolites that exhibited statistically significant changes are bolded.

prostate cancer is known to cause adverse effects on all of these processes. The possibility of clinically meaningful interaction between ADT, bile acids, and these metabolic derangements has not yet been explored.

Our preliminary observations about changes in bile acids must be validated. The present analyses provide relative changes but do not quantify changes in the bile acid pool or define the relative changes in individual primary, secondary, and tertiary bile acids. Further investigation of the ADT-induced elevations in bile acid levels may yield mechanistic insights. It may also lead to opportunities for therapeutic intervention as bile acid-binding agents have an established role in the management of patients with disordered glucose metabolism.

Orally administered bile acid sequestrants have long been commercially available as cholesterol-lowering agents that work by preventing reabsorption of bile acids in the enterohepatic circulation, thereby shunting cholesterol production to replace what is lost (33). More recently, therapeutic manipulation of bile acids with sequestrants has been shown to improve whole body insulin sensitivity (34), and to improve markers of glycemic control among diabetic men in the general population (33, 35). With further investigation of the

present observations, these agents may find a rational role in the medical management of men who suffer from treatment-induced metabolic effects such as IR or hypertriglyceridemia.

Fatty acid oxidation decreased during therapy as evidenced by decreases in markers of lipid beta-oxidation (acetyl-carnitines and ketone bodies) and decreases in the byproducts of omega-oxidation, a secondary pathway to fatty acid metabolism. Although this pattern was nearly universal among detected biochemicals, not all decreases were statistically significant. These data suggest that lipolysis and beta-oxidation of fatty acids are decreased during the first 3 months of ADT. This observation was unexpected as it reflects the absence of a catabolic state. Relative resistance to insulin is a previously observed effect of ADT and causes a catabolic state in the general population. Important future directions include validation of this finding and further investigation of its implications for men receiving ADT for the treatment of prostate cancer. Because the present analysis did not follow men beyond the first 3 months of treatment, changes in fatty acid oxidation during prolonged ADT remain to be characterized.

We observed significant changes in the opposite of the expected direction for 2 previously described markers of IR.

Table 4. Changes in biochemicals relevant to IR from baseline to 3 months

Subpathway	Biochemical name	Fold of change, month 3 versus baseline	P value for paired t test, month 3 versus baseline	q value for paired t test, month 3 versus baseline
Valine, leucine, and isoleucine metabolism	2-hydroxybutyrate (2-HB)	0.84	0.030	0.120
	3-methyl-2-oxobutyrate	0.96	0.553	0.439
	3-methyl-2-oxovalerate	0.99	0.548	0.439
	Beta-hydroxyisovalerate	0.94	0.203	0.319
	Isoleucine	0.91	0.066	0.196
	Leucine	0.93	0.118	0.254
	Valine	0.94	0.272	0.356
	2-hydroxyisobutyrate	1.02	0.856	0.526
	3-hydroxyisobutyrate	0.94	0.328	0.356
	4-methyl-2-oxopentanoate	0.97	0.546	0.439
	Alpha-hydroxyisovalerate	0.91	0.016	0.092
	Isobutyrylcarnitine	1.01	0.802	0.512
	2-methylbutyrylcarnitine	0.88	0.039	0.141
	Isovalerylcarnitine	0.99	0.475	0.414
	Hydroxyisovaleroyl carnitine	0.97	0.797	0.512
	Tiglyl carnitine	0.98	0.839	0.522
Methylglutaryl carnitine	0.86	0.072	0.202	

NOTE: All values are normalized in terms of raw area counts. "Fold change month 3 versus baseline" denotes month 3 level divided by baseline level of each biochemical name (i.e., fold change of 0.76 denotes a 24% decrease). Biochemical fold differences were generated based on group means with ratios greater than one representing fold increases and ratios less than one representing fold decreases.

Metabolites that exhibited statistically significant changes are bolded.

2-HB fell significantly during the first 3 months of hormonal therapy and BCKDH complex products were stable to lower at 3 months. Increase in 2-HB was identified as a biomarker of IR in the Relationship of Insulin Sensitivity to Cardiovascular Risk (RISK) study. In that cohort of 399 nondiabetic subjects, plasma metabolomic analyses revealed 2-HB to be the biomarker best able to discriminate between insulin sensitive and insulin resistant men (as defined by gold-standard hyperinsulinemic euglycemic clamp testing; ref. 24). Despite the fact that fasting insulin has previously been shown to increase during the first 3 months of ADT (14), 2-HB significantly declined from baseline to 3 months in the present analysis.

Circulating branched chain keto acids (BCKA) reflect muscle breakdown and can increase in catabolic states such as IR. Circulating branched chain amino acid levels have previously been shown to be significantly higher in obese subjects than in lean subjects. Furthermore, branched chain amino acid–related metabolites have been shown to correlate positively with homeostatic model assessment, a validated measure of IR, even after adjustment for body weight (25). We observed stability to slight declines in most measured BCKAs.

The clinical significance of these observations about previously identified biomarkers of IR is not known but is

surprising given that a significant increase in serum insulin has been previously described in this clinical setting (14). It is possible that the pathophysiology of ADT-induced IR is different from the pathophysiology of IR in other clinical settings. It is also likely that biomarkers of early changes in insulin induced by the first 3 months of ADT are different from biomarkers of IR that emerge chronically within the general population. For instance, circulating insulin levels are elevated early in the natural history of type II diabetes but fall with time. Further studies are needed to better characterize the mechanism(s) responsible for ADT-associated IR.

The present analyses feature notable limitations. First, metabolomic analyses are limited by the breadth of identifiable compounds within the experimental platform. Many compound peaks were not identified within the Metabolon library (212 unidentified among 504 total, 42%). Of the 88 compounds that changed significantly, 32 were unidentified (36%). The identity and biologic significance of these compounds is therefore not known. Second, some molecules of clinical relevance to metabolic health were not identified. For example, many products of cholesterol metabolism were identified but testosterone itself was not. Third, this technique carries the potential for chance observations, given the large number of

molecules screened. Fourth, changes in some biochemicals have been shown to emerge far sooner than 3 months after a drop in testosterone levels (e.g., insulin; refs. 36, 37). ADT-induced metabolic changes cannot be fully characterized through the study of just two time points. Finally, it is important to note that the metabolomic profile of ADT-induced changes during the first 3 months of therapy does not speak to the long-term effects of treatment. Initiation of a GnRH agonist causes a rapid and drastic change in the host hormonal environment that may later lead to an altogether different metabolomic profile during prolonged treatment.

In addition, it is important to emphasize that the methodology used for these analyses provides only relative quantitation of identified compounds. For example, this analysis detected a statistically significant 1.9-fold increase in the primary bile acid cholate but is not able to accurately specify plasma levels of cholate for the 2 experimental time points. This limitation is accepted in the context of broad screening but necessitates subsequent quantitative validation of key findings. Key future directions therefore include quantitative analyses of ADT-induced changes in bile acids and in biomarkers of fatty acid metabolism and IR.

Previously published literature on the metabolic effects of ADT has focused on obesity-related complications such as hyperlipidemia and IR. To search more broadly for clinically important ADT-induced metabolic changes, we carried out unbiased metabolomic analyses on plasma samples from men receiving their first 3 months of GnRH agonist therapy. These analyses revealed treatment-induced declines in androgens as well as unexpected changes in bile acids and in biomarkers of lipid metabolism and IR. One key future direction will be to quantitate baseline and on-treatment levels of the compounds identified with this

technique. Although metabolic changes clearly occur by 3 months of treatment, changes in men receiving longer durations of therapy are also clinically relevant and worthy of additional study. Further mechanistic insights are needed to better promote the metabolic health of men receiving GnRH agonist therapy for prostate cancer.

Disclosure of Potential Conflicts of Interest

E.D. Karoly is employed in Metabolon and owns stock in Metabolon. No potential conflicts of interest were disclosed by the other authors.

Authors' Contributions

Conception and design: P.J. Saylor, M.R. Smith
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): E.D. Karoly, M.R. Smith
Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): P.J. Saylor, E.D. Karoly, M.R. Smith
Writing, review, and/or revision of the manuscript: P.J. Saylor, E.D. Karoly, M.R. Smith
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): M.R. Smith

Acknowledgments

The authors thank Nancy L. Keating, MD, MPH, and Jonathan McDunn, PhD, for their valuable input.

Grant Support

This work is supported by grants from the Prostate Cancer Foundation (to M.R. Smith and P.J. Saylor), American Society of Clinical Oncology (to P.J. Saylor), and NIH (5K24CA121990-02; to M.R. Smith).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received December 13, 2011; revised April 27, 2012; accepted April 29, 2012; published OnlineFirst May 15, 2012.

References

- Bolla M, Collette L, Blank L, Warde P, Dubois JB, Mirimanoff RO, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. *Lancet* 2002;360:103-6.
- Bolla M, de Reijke TM, Van Tienhoven G, Van den Bergh AC, Oddens J, Poortmans PM, et al. Duration of androgen suppression in the treatment of prostate cancer. *N Engl J Med* 2009;360:2516-27.
- D'Amico AV, Manola J, Loffredo M, Renshaw AA, DellaCroce A, Kantoff PW. 6-month androgen suppression plus radiation therapy vs. radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. *JAMA* 2004;292:821-7.
- Denham JW, Steigler A, Lamb DS, Joseph D, Mameghan H, Turner S, et al. Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. *Lancet Oncol* 2005;6:841-50.
- Pilepich MV, Winter K, Lawton CA, Krisch RE, Wolkov HB, Movsas B, et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma—long-term results of phase III RTOG 85-31. *Int J Radiat Oncol Biol Phys* 2005;61:1285-90.
- Horwitz EM, Bae K, Hanks GE, Porter A, Grignon DJ, Brereton HD, et al. Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. *J Clin Oncol* 2008;26:2497-504.
- Jones CU, Hunt D, McGowan DG, Amin MB, Chetner MP, Bruner DW, et al. Radiotherapy and short-term androgen deprivation for localized prostate cancer. *N Engl J Med* 2011;365:107-18.
- Messing EM, Manola J, Yao J, Kiernan M, Crawford D, Wilding G, et al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. *Lancet Oncol* 2006;7:472-9.
- Walsh PC. Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council trial. The Medical Research Council Prostate Cancer Working Party Investigators Group. *J Urol* 1997;158:1623-4.
- Smith MR, Finkelstein JS, McGovern FJ, Zietman AL, Fallon MA, Schoenfeld DA, et al. Changes in body composition during androgen deprivation therapy for prostate cancer. *J Clin Endocrinol Metab* 2002;87:599-603.
- Smith MR. Changes in fat and lean body mass during androgen-deprivation therapy for prostate cancer. *Urology* 2004;63:742-5.
- Smith MR, Lee H, McGovern F, Fallon MA, Goode M, Zietman AL, et al. Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: differences from the classic metabolic syndrome. *Cancer* 2008;112:2188-94.
- Kim H, Moreira D, Smith M, Presti JJ, Aronson W, Terris M, et al. A natural history of weight change in men with prostate cancer on androgen deprivation therapy: results from the SEARCH database. *BJU Int* 2010;107:924-8.

14. Smith MR, Lee H, Nathan DM. Insulin sensitivity during combined androgen blockade for prostate cancer. *J Clin Endocrinol Metab* 2006;91:1305–8.
15. Dockery F, Bulpitt CJ, Agarwal S, Donaldson M, Rajkumar C. Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia. *Clin Sci (Lond)* 2003;104:195–201.
16. Eri LM, Urdal P, Bechensteen AG. Effects of the luteinizing hormone-releasing hormone agonist leuprolide on lipoproteins, fibrinogen and plasminogen activator inhibitor in patients with benign prostatic hyperplasia. *J Urol* 1995;154:100–4.
17. Efsthathiou JA, Bae K, Shipley WU, Hanks GE, Pilepich MV, Sandler HM, et al. Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85–31. *J Clin Oncol* 2009;27:92–9.
18. Keating NL, O'Malley AJ, Freedland SJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. *J Natl Cancer Inst* 2010;102:39–46.
19. Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. *J Clin Oncol* 2006;24:4448–56.
20. Saigal CS, Gore JL, Krupski TL, Hanley J, Schonlau M, Litwin MS. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. *Cancer* 2007;110:1493–500.
21. Tsai HK, D'Amico AV, Sadetsky N, Chen MH, Carroll PR. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. *J Natl Cancer Inst* 2007;99:1516–24.
22. Van Hemelrijck M, Garmo H, Holmberg L, Ingelsson E, Bratt O, Bill-Axelsson A, et al. Absolute and relative risk of cardiovascular disease in men with prostate cancer: results from the population-based PCBaSe Sweden. *J Clin Oncol* 2010;28:3448–56.
23. Alibhai SM, Duong-Hua M, Sutradhar R, Fleshner NE, Warde P, Cheung AM, et al. Impact of androgen deprivation therapy on cardiovascular disease and diabetes. *J Clin Oncol* 2009;27:3452–58.
24. Gall WE, Beebe K, Lawton KA, Adam KP, Mitchell MW, Nakhle PJ, et al. Alpha-hydroxybutyrate is an early biomarker of insulin resistance and glucose intolerance in a nondiabetic population. *PLoS One* 2010;5:e10883.
25. Newgard CB, An J, Bain JR, Muehlbauer MJ, Stevens RD, Lien LF, et al. A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. *Cell Metab* 2009;9:311–26.
26. Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. *Nature* 2009;457:910–4.
27. Evans AM, DeHaven CD, Barrett T, Mitchell M, Milgram E. Integrated, nontargeted ultrahigh performance liquid chromatography/electrospray ionization tandem mass spectrometry platform for the identification and relative quantification of the small-molecule complement of biological systems. *Anal Chem* 2009;81:6656–67.
28. Smith JC, Bennett S, Evans LM, Kynaston HG, Parmar M, Mason MD, et al. The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. *J Clin Endocrinol Metab* 2001;86:4261–7.
29. Reitman ZJ, Jin G, Karoly ED, Spasojevic I, Yang J, Kinzler KW, et al. Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome. *Proc Natl Acad Sci U S A* 2011;108:3270–5.
30. Landaas S. The formation of 2-hydroxybutyric acid in experimental animals. *Clin Chim Acta* 1975;58:23–32.
31. Walser M. Role of branched-chain ketoacids in protein metabolism. *Kidney Int* 1990;38:595–604.
32. Prawitt J, Caron S, Staels B. Bile Acid metabolism and the pathogenesis of type 2 diabetes. *Cur Diab Rep* 2011;11:160–6.
33. Kobayashi M, Ikegami H, Fujisawa T, Nojima K, Kawabata Y, Noso S, et al. Prevention and treatment of obesity, insulin resistance, and diabetes by bile acid-binding resin. *Diabetes* 2007;56:239–47.
34. Schwartz SL, Lai YL, Xu J, Abby SL, Misir S, Jones MR, et al. The effect of colesevelam hydrochloride on insulin sensitivity and secretion in patients with type 2 diabetes: a pilot study. *Metab Syndr Relat Disord* 2010;8:179–88.
35. Prawitt J, Staels B. Bile acid sequestrants: glucose-lowering mechanisms. *Metab Syndr Relat Disord* 2010;8 Suppl 1:S3–8.
36. Rubinow KB, Snyder CN, Amory JK, Hoofnagle AN, Page ST. Acute testosterone deprivation reduces insulin sensitivity in men. *Clin Endocrinol (Oxf)* 2012;76:281–8.
37. Yialamas MA, Dwyer AA, Hanley E, Lee H, Pitteloud N, Hayes FJ. Acute sex steroid withdrawal reduces insulin sensitivity in healthy men with idiopathic hypogonadotropic hypogonadism. *J Clin Endocrinol Metab* 2007;92:4254–9.